NorthWest Biotherapeutics Inc (NWBO)

[sentiment_stocks]

Now imagine clinicians saying to their subgroup patients that they won't respond to chemo/rad and maybe should have checkpoint inhibitors before L and ICLC with it soon after surgery to improve outcomes.

Because...

In a person with cancer, if antigen-specific T cells are present and impaired by the tumor and the surrounding microenvironment, they can be awakened by the drug prior to surgery. In contrast, after surgery, the drug doesn’t stimulate patients’ T cells because those T cells are removed with the tumor.

https://newsroom.ucla.edu/releases/recurrent-glioblastoma-immunotherapy-before-surgery

And with this current trial that's ongoing at UCLA, we'll see if these results are further improved when L is added to the mix. They'll determine the efficacy of those results using keytruda before surgery and afterwards, then perform the surgery, next make the DCVax-L vaccine -- made at UCLA but still it's DCVax-L, directly told to me face-to-face by UCLA's Dr.s Linda Liau AND Phioanh Leia Nghiemphu.

That described combined treatment arm is being compared to another using DCVax-L all by its lonesome self.

https://clinicaltrials.gov/ct2/show/NCT04201873?term=cloughesy&draw=2&rank=3